Weber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42(1):237. https://doi.org/10.1007/s00345-024-04949-8.

Article  PubMed  PubMed Central  Google Scholar 

Al Hussein Al Awamlh B, Chang SS. Novel therapies for high-risk non-muscle invasive bladder cancer. Curr Oncol Rep. 2023;25(2):83–91. https://doi.org/10.1007/s11912-022-01350-9.

Article  CAS  PubMed  Google Scholar 

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5; discussion 75 – 7. https://doi.org/10.1016/j.eururo.2005.12.031.

Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022;19(5):280–94. https://doi.org/10.1038/s41585-022-00578-1.

Article  PubMed  Google Scholar 

Kata SG, Zreik A, Ahmad S, Chlosta P, Aboumarzouk O. Concurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy? Cent Eur J Urol. 2016;69(4):334–40. https://doi.org/10.5173/ceju.2016.896.

Article  CAS  Google Scholar 

Mulawkar PM, Sharma G, Tamhankar A, Shah U, Raheem R. Role of macroscopic image enhancement in diagnosis of Non-Muscle-Invasive bladder cancer: an analytical review. Front Surg. 2022;9:762027. https://doi.org/10.3389/fsurg.2022.762027.

Article  PubMed  PubMed Central  Google Scholar 

Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder Cancer. StatPearls. Treasure Island (FL)2025.

Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010;4(1):56–64. https://doi.org/10.5489/cuaj.777.

Article  PubMed  PubMed Central  Google Scholar 

Strandgaard T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, Prip F, Rasmussen J, et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur Urol. 2024;85(1):82–92. https://doi.org/10.1016/j.eururo.2023.07.014.

Article  CAS  PubMed  Google Scholar 

Clark O, Sarmento T, Eccleston A, Brinkmann J, Picoli R, Daliparthi V, et al. Economic impact of bladder cancer in the USA. Pharmacoeconomics- Open. 2024;8(6):837–45. https://doi.org/10.1007/s41669-024-00512-8.

Article  PubMed  PubMed Central  Google Scholar 

Lee LJ, Kwon CS, Forsythe A, Mamolo CM, Masters ET, Jacobs IA. Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews. Clinicoecon Outcomes Res. 2020;12:693–709. https://doi.org/10.2147/CEOR.S274951.

Article  PubMed  PubMed Central  Google Scholar 

Jung YL, Tompa E, Longo C, Kalcevich C, Kim J, Song C, et al. The economic burden of bladder cancer due to occupational exposure. J Occup Environ Med. 2018;60(3):217–25. https://doi.org/10.1097/JOM.0000000000001242.

Article  PubMed  Google Scholar 

Joyce DD, Sharma V, Williams SB. Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature. Pharmacoeconomics. 2023;41(7):751–69. https://doi.org/10.1007/s40273-023-01273-8.

Article  PubMed  Google Scholar 

Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32(11):1093–104. https://doi.org/10.1007/s40273-014-0194-2.

Article  PubMed  Google Scholar 

New Drug Application for Cysview (hexaminolevulinate hydrochloride). [Internet]. Silver Spring (MD): Food and Drug Administration (US); [cited 2025 Nov 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022555Orig1s000MedR.pdf.: (2010). Accessed.

Hayashi M, Fukuhara H, Inoue K, Shuin T, Hagiya Y, Nakajima M, et al. The effect of iron ion on the specificity of photodynamic therapy with 5-Aminolevulinic acid. PLoS ONE. 2015;10(3):e0122351. https://doi.org/10.1371/journal.pone.0122351.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakai Y, Tatsumi Y, Hori S, Morizawa Y, Iida K, Onishi K, et al. 5–Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating Heme synthesis. Oncol Rep. 2022;48(4). https://doi.org/10.3892/or.2022.8401.

Bazargani ST, Djaladat H, Schuckman AK, Hugen CM, Daneshmand S. Optimizing diagnosis of urothelial bladder cancer with blue light cystoscopy via recognition of False-Positive lesions. Videourology. 2018;32(2). https://doi.org/10.1089/vid.2017.0073.

Ghoreifi A, Daneshmand S. Technical considerations to minimize false-positive findings in blue light cystoscopy for nonmuscle-invasive bladder cancer. J Urol. 2025;213(1):5–7. https://doi.org/10.1097/JU.0000000000004250.

Article  PubMed  Google Scholar 

Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533–8. https://doi.org/10.1097/JU.0000000000003846.

Article  PubMed  Google Scholar 

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9. https://doi.org/10.1016/j.juro.2016.06.049.

Article  PubMed  Google Scholar 

Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—a summary of the 2024 Guidelines Update. Eur Urol. 2024;86(6):531–49. https://doi.org/10.1016/j.eururo.2024.07.027.

Article  PubMed  Google Scholar 

Guidelines NCCN. Version 1.2025 bladder cancer. National Comprehensive Cancer Network.

Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, et al. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: revision working position paper. Int J Urol. 2020;27(5):362–8. https://doi.org/10.1111/iju.14210.

Article  PubMed  Google Scholar 

Bhindi B, Kool R, Kulkarni GS, Siemens DR, Aprikian AG, Breau RH, et al. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - full-text. Can Urol Assoc J. 2021;15(8):E424–60. https://doi.org/10.5489/cuaj.7367.

Article  PubMed  PubMed Central  Google Scholar 

Jin Y-H, Zeng X-T, Liu T-Z, Bai Z-M, Dou Z-L, Ding D-G, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Military Med Res. 2022;9(1). https://doi.org/10.1186/s40779-022-00406-y.

Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, et al. Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trial. Photodiagnosis Photodyn Ther. 2025;53:104554. https://doi.org/10.1016/j.pdpdt.2025.104554.

Article  CAS  PubMed  Google Scholar 

Ladi-Seyedian S-S, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, et al. Racial differences in the detection rate of bladder cancer using blue light cystoscopy: insights from a multicenter registry. Cancers. 2024;16(7):1268. https://doi.org/10.3390/cancers16071268.

Article  PubMed  PubMed Central  Google Scholar 

Watanabe K, Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, et al. Significance of 5-aminolevulinic acid-mediated photodynamic diagnosis following standard transurethral resection in non-muscle invasive bladder cancer. Cancer Diagn Progn. 2021;1(3):201–5. https://doi.org/10.21873/cdp.10027.

Article  PubMed  PubMed Central  Google Scholar 

Andersson M, Berger M, Zieger K, Malmstrom PU, Blackberg M. The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem. Scand J Urol. 2021;55(4):263–7. https://doi.org/10.1080/21681805.2021.1928746.

Article  PubMed  Google Scholar 

Lacetera V, Cantoro U, Montesi L, Cantoro D, Cervelli B, Cicetti A, et al. Blue light cystoscopy with hexylaminolevulinate: our 7 years experience. Arch Ital Urol Androl. 2017;89(1):39–41. https://doi.org/10.4081/aiua.2017.1.39.

Article  PubMed  Google Scholar 

Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM et al. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Urol Oncol. 2018;36(8):361 e1- e6. https://doi.org/10.1016/j.urolonc.2018.04.013

Morelli M, Baboudjian M, Vanacore D, Gondran-Tellier B, McManus R, Karsenty G, et al. Early photodynamic diagnosis cystoscopy after Bacillus Calmette-Guerin (BCG) induction for high-risk nonmuscle invasive bladder cancer significantly increased the detection of BCG refractory tumors. J Endourol. 2021;35(12):1824–8. https://doi.org/10.1089/end.2021.0313.

Article  PubMed  Google Scholar 

Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non‐muscle‐invasive bladder cancer (NMIBC)? BJU Int. 2012;109(4):549–56. https://doi.org/10.1111/j.1464-410x.2011.10374.x.

Article  PubMed  Google Scholar 

McElree IM, Steinberg RL, Mott SL, Hougen HY, O’Donnell MA, Packiam VT. The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC. Bladder Cancer. 2025;11(2):2352373525132